Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of enantioselective high-performance liquid chromatography-tandem mass spectrometry method for the quantitative determination of 3,4-methylenedioxy-methamphetamine (MDMA) and its phase-1 metabolites in human biological fluids

  • Lo Faro, Alfredo
  • Sprega, Giorgia
  • Beradinelli, Diletta
  • Tini, Anstasio
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Papaseit, Esther|||0000-0003-2620-4274
  • Berretta, Paolo|||0000-0002-1748-5628
  • Di Giorgi, Alessandro|||0000-0003-2997-221X
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Takaishvili, Nino
  • Farkas, Tivadar
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Chankvetadze, Bezhan
In the present study enantioselective high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods were developed for the quantitative determination of 3,4-methylenedioxy-methamphetamine (MDMA) and its major phase-1 metabolites 4-hydroxy-3-methoxyamphetamine (HMA), 4-hydroxy-3-methoxymethamphetamine (HMMA) and 3,4-methylenedioxyamphetamine (MDA) in human plasma, sweat, oral fluid (OF) and urine. The simultaneous separation of all these compounds and their respective enantioseparation was accomplished on two polysaccharide-based chiral columns. The Lux AMP column with a proprietary chiral selector enabled baseline separation of the enantiomers of MDMA, HMA and HMMA while MDA enantiomers could not be separated with this column under the experimental conditions used in this study. The Lux i-Amylose-3 column based on amylose tris(5-chloro-3-methylphenylcarbamate) as chiral selector baseline-separated the enantiomers of MDMA, HMMA and MDA while the enantiomers of HMA could not be separated. Thus, the various samples were analyzed by using both columns alternatively in combinations with acetonitrile containing 25% (v/v) 5 mM ammonium bicarbonate buffer at pH 11.0 as mobile phase. Analysis time was less than 4 min with the Lux AMP column and less than 6 min with the Lux i-Amylose-3 column. Both methods were validated and applied to the enantioselective determination of MDMA and its phase-I metabolites in human biological fluids, and enantioselective metabolism of MDMA was confirmed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Metabolic profile of N-ethylhexedrone, N-ethylpentedrone, and 4-chloromethcathinone in urine samples by UHPLC-QTOF-HRMS

  • Massano, Marta
  • Nuñez-Montero, Melani
  • Papaseit, Esther|||0000-0003-2620-4274
  • Hladun, Olga|||0000-0002-6230-5876
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Ventura, Mireia|||0000-0003-1133-6872
  • Marchei, Emilia|||0000-0002-7158-6032
  • Alladio, Eugenio
  • Gerace, Enrico
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Salomone, Alberto
Forensic laboratories are constantly required to identify new drugs and their metabolites. N-ethylhexedrone (NEH, HEXEN), N-Ethylpentedrone (NEP), and 4-Chloromethcathinone (4-CMC, clephedrone) are synthetic substances structurally related to natural cathinone, alkaloid present in the leaves of the Catha edulis (Khat) plant. These synthetic cathinones (SC) are members of the heterogenous family of new psychoactive substances (NPS) that raised major concerns in scientific and forensic communities over the past years due to their widespread consumption. In this context, we investigated their metabolic profile using of UHPLC-QTOF-HRMS to elucidate the distribution of the parent drug and its metabolites in urine samples over time. Initially, both male and female volunteers were divided into three groups and eight subjects of each group were administered intranasally or orally with one SC (20-40 mg of NEH or NEP intranasal, 100-150 mg of 4-CMC oral). Urine samples were collected at 0-2 and 2-4 or 2-5 h. Urine (50 μL) was diluted 1:2 with acetonitrile/methanol (95:5) and injected into the UHPLC-QTOF-HRMS. Phase-I and phase-II metabolites were identified on the basis of fragmentation patterns and exact masses. Several phase-I and glucuronide-phase-II metabolites were identified in urine samples. Keto group reduction, hydroxylation and dealkylation were the common metabolic pathways identified for all cathinones and the presence of NEH-glucuronide, NEP-glucuronide and 4-CMC-glucuronide was also relevant. Significant is the slower metabolite formation for 4-CMC, which was detected at high concentrations in its original form even 5 h after administration, due to its long half-life and low intrinsic clearance compared to the other SCs. UHPLC-QTOF-HRMS demonstrated a considerable capability to semi-quantify the three synthetic cathinones and identify the target metabolites with high reliability. The introduction of new target compounds improves the efficiency of toxicological screening analysis on real samples and extends the window of detection of the SCs in biological matrices.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Challenges encountered in the enantioselective analysis of new psychoactive substances exemplified by clephedrone (4-CMC)

  • Jorbenadze, Saba
  • Khatiashvili, Tamar
  • Giunashvili, Lasha
  • Tchelidze, Aluda
  • Lo Faro, Alfredo Fabrizio|||0000-0002-0240-5277
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Papaseit, Ester
  • Nuñez-Montero, Melani
  • Carlier, Jeremy
  • Farkas, Tivadar
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Chankvetadze, Bezhan
In this study we report on efforts to develop an enantioselective method for the detection of the drug of abuse clephedrone (1-(4-chlorophenyl)-2-(methylamino)-1-propanone (4-chloromethcathinone, also known as 4-CMC or para-chloro-methcathinone)) and its phase-1 metabolites in human biological fluids. The major goal is not to only report results, but primarily to emphasize the various challenges encountered when developing a reliable analytical method for the detection and quantification of novel psychoactive substances (NPS) and their metabolites in the matrix of interest. Such challenges start with the lack of chemical stability of some NPS in biological matrices. Additionally, most often metabolites are unavailable in pure form to serve as analytical standards, just as deuterated standards for native drugs and metabolites are frequently not commercially available. Furthermore, if the NPS is chiral, enantiomerically pure standards with known absolute stereochemistry are required, as well as a stereochemical stability of a drug and its metabolites becomes an issue. In addition, the chirality of a NPS significantly increases the number of species to be detected in the sample and thus challenges the development of an adequate separation method. These issues are shortly addressed, and some solutions offered in this manuscript.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acute pharmacological effects of α-PVP in humans, a naturalistic observational study

  • Rosa, Georgina de la
  • Papaseit, Esther|||0000-0003-2620-4274
  • Hladun, Olga|||0000-0002-6230-5876
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Caicedo, Dolly Andrea
  • Argote Oramas, Martha Catalina
  • Martín, Soraya|||0009-0008-3761-9217
  • Ventura, Mireia|||0000-0003-1133-6872
  • La Maida, Nunzia|||0000-0003-0127-4225
  • Di Trana, Annagiulia|||0000-0002-8456-0827
  • Graziano, Silvia|||0000-0002-5609-0872
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
Alpha-pyrrolidinopentiophenone (α-PVP) is a commonly consumed analogue of pyrovalerone, a synthetic cathinone with psychostimulant properties similar to those of 3,4-Methylenedioxypyrovalerone (MDPV) and cocaine. Since the pharmacology of α-PVP remains scarcely studied, we aimed to evaluate the acute pharmacological effects and its abuse potential in humans after intranasal administration. We carried out a non-controlled observational study in a naturalistic environment in nine participants (3 women and six men) with a previous history of psychostimulant use. Participants self-administered a single intranasal dose of 10mg or 20mg of α-PVP. The outcomes included physiological effects (systolic and diastolic blood pressure, heart rate, and temperature) and subjective effects (Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire_VESSPA-SSE, the short form of the Addiction Research Center Inventory questionnaire_ARCI and visual analog scales_VASs) and were measured at different time points (0, 20 and 40 minutes and 1, 1.5, 2, 2.5, 3, 4 and 5 hours). An acute increase in blood pressure and heart rate was observed that peaked 40 minutes after administration. Subjective effects also showed a rapid onset and disappeared 3 to 5 hours after administration. α-PVP showed psychostimulant properties similar to those displayed by cocaine and empathogenic effects commonly associated with MDMA and other cathinones (eg. methylone) consumption.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Oral Fluid Concentrations and Pharmacological Effects of Clephedrone and Methylone in Humans

  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Núñez-Montero, Melani
  • Hladun, Olga|||0000-0002-6230-5876
  • Rosa, Georgina de la
  • Martín, Soraya|||0009-0008-3761-9217
  • Videla, Sebastián|||0000-0001-5049-1379
  • Martínez-Couselo, Silvia
  • Ventura, Mireia|||0000-0003-1133-6872
  • La Maida, Nunzia|||0000-0003-0127-4225
  • Di Trana, Annagiulia|||0000-0002-8456-0827
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Torrens, Marta
  • Pichini, Simona
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Papaseit, Esther|||0000-0003-2620-4274
Synthetic cathinones represent the second most frequently reported group of new psychoactive substances identified annually, according to the United Nations. It remains unknown whether specific derivatives differ in the onset of effects related to absorption kinetics. Clephedrone (4-chloromethcathinone, 4-CMC) has been among the most frequently seized cathinones in recent years; however, available data on its pharmacology and abuse potential remain scarce. A non-controlled, prospective, observational study was conducted involving eight healthy volunteers (six women) who self-administered a single oral dose of clephedrone (100 or 150 mg). Study variables were assessed at baseline and over a 5-h period following administration, including vital signs and subjective effects. Oral fluid concentrations of clephedrone and cortisol were determined. For comparison, this article also presents previously unpublished data from a pilot study in which 12 healthy male participants received 150 or 200 mg of methylone under comparable conditions to evaluate effects. Results indicated that both clephedrone and methylone produced stimulant-like subjective effects. However, clephedrone exhibited a delayed onset and peak of effects compared with methylone, indicating a clinically relevant pharmacokinetic difference. Both substances were detected in oral fluid, with peak concentrations occurring later following clephedrone administration, consistent with its delayed pharmacodynamic profile.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis

  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Pérez-Acevedo, Ana Pilar|||0000-0001-5647-4529
  • Pacifici, Roberta
  • Mannocchi, Giulio
  • Gottardi, Massimo
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Martín, Soraya|||0009-0008-3761-9217
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Inhalation by vaporization is a useful application mode for medical cannabis. In this study, we present the disposition of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, and their metabolites in serum, oral fluid, and urine together with the acute pharmacological effects in 14 healthy individuals treated with vaporized medical cannabis. THC and CBD peaked firstly in serum and then in oral fluid, with higher concentrations in the first biological matrices and consequent higher area under the curve AUCs. Acidic precursors Δ-9-tetrahydrocannabinolic acid A (THCA) and cannabidiolic acid (CBDA) showed a similar time course profile but lower concentrations due to the fact that vaporization partly decarboxylated these compounds. All THC and CBD metabolites showed a later onset with respect to the parent compounds in the absorption phase and a slower decrease to baseline. In agreement with serum kinetics, THC-COOH-GLUC and 7-COOH-CBD were the significantly most excreted THC and CBD metabolites. The administration of vaporized medical cannabis induced prototypical effects associated with the administration of cannabis or THC in humans, with a kinetic trend overlapping that of parent compounds and metabolites in serum. The pharmacokinetics of cannabinoids, their precursors, and their metabolites in biological fluids of individuals treated with vaporized medical cannabis preparations showed a high interindividual variability as in the case of oral medical cannabis decoction and oil. Inhaled medical cannabis was absorbed into the organism earlier than decoction and oil. Cannabinoids reached higher systemic concentrations, also due to the fact that the acid precursors decarboxylated to parent cannabinoids at high temperatures, and consequently, the physiological and subjective effects occurred earlier and resulted with higher intensity. No serious adverse effects were observed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis

  • Pérez-Acevedo, Ana Pilar|||0000-0001-5647-4529
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Pacifici, Roberta
  • Mannocchi, Giulio
  • Gottardi, Massimo
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Martín, Soraya|||0009-0008-3761-9217
  • Di Trana, Annagiulia|||0000-0002-8456-0827
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
The use of cannabis flowering tops with standardized amounts of active phytocannabinoids was recently authorized in several countries to treat several painful pathological conditions. The acute pharmacological effects and disposition of Δ-9-tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors and THC metabolites after oil and decoction administration have been already described. In this study, the disposition of CBD metabolites: 7-carboxy-cannabidiol (7-COOH-CBD), 7-hydroxycannabidiol (7-OH-CBD), 6-α-hydroxycannabidiol (6-α-OH-CBD), and 6-β-hydroxycannabidiol (6-β-OH-CBD) in the serum and urine of healthy volunteers was presented. Thirteen healthy volunteers were administered 100 mL of cannabis decoction in the first experimental session and, after 15 days of washout, 0.45 mL of oil. Serum and urine samples were collected at different time points, and the CBD metabolites were quantified by ultra-high-performance liquid chromatography-tandem mass spectrometry. The most abundant serum metabolite was 7-COOH-CBD, followed by 7-OH-CBD, 6-β-OH-CBD, and6-α-OH-CBD, after decoction and oil. Both 7-OH-CBD and the 6-α-OH-CBD showed similar pharmacokinetic properties following administration of both cannabis preparations, whereas 7-COOH and 6-α-OH-CBD displayed a significant higher bioavailability after decoction consumption. All CBD metabolites were similarly excreted after oil and decoction intake apart from 6-α-OH-CBD, which had a significantly lower excretion after oil administration. The pharmacokinetic characterization of CBD metabolites is crucial for clinical practice since the cannabis herbal preparations are increasingly used for several pathological conditions.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Abuse Potential of Cathinones in Humans, a Systematic Review

  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Torres, Adrian
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Hladun, Olga|||0000-0002-6230-5876
  • Núñez-Montero, Melani
  • Rosa, Georgina de la
  • Torrens, Marta
  • Fuster, Daniel|||0000-0003-1262-5860
  • Muga, Roberto|||0000-0001-6301-431X
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Introduction and objective: Assessing the abuse potential of new substances with central nervous system activity is essential for preventing possible risks of misuse and addiction. The same methodology is recommended for the evaluation of the abuse potential of recreational drugs. This systematic review aims to assess the pharmacological effects related to the abuse potential and pharmacokinetics of cathinones, which are evaluated in both experimental and prospective observational studies in humans. Materials and Methods: A systematic search of the published literature was conducted to retrieve studies that had administered cathinone, mephedrone, methylone, and diethylpropion to evaluate their acute pharmacological effects related to abuse potential. Results: The search yielded 583 results, 18 of which were included to assess the abuse potential of cathinone (n = 5), mephedrone (n = 7), methylone (n = 1), and diethylpropion (n = 5). All four substances induce stimulant and euphorigenic effects that resemble those of amphetamines and MDMA, and their different intensities may be associated with varying levels of abuse potential. Conclusions: Cathinone, mephedrone, methylone, and diethylpropion induce a range of desirable and reinforcing effects that may, to some extent, result in abuse potential. Further investigation is needed to minimize and prevent their impact on society and public health.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological effects of methylone and MDMA in humans

  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Hladun, Olga|||0000-0002-6230-5876
  • Núñez-Montero, Melani
  • Rosa, Georgina de la
  • Martín, Soraya|||0009-0008-3761-9217
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Carabias, Lydia
  • Kelmendi, Benjamin
  • Taoussi, Omayema
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Fonseca, Francina|||0000-0002-0779-6545
  • Torrens, Marta
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Papaseit, Esther|||0000-0003-2620-4274
Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we aimed to evaluate the acute pharmacological effects of methylone and its abuse potential in humans when compared with that of MDMA following oral administration under controlled conditions. Seventeen participants of both sexes (14 males, 3 females) with a previous history of psychostimulant use completed a randomized, double-blind, placebo-controlled, crossover clinical trial. Participants received a single oral dose of 200 mg of methylone, 100 mg of MDMA, and a placebo. The variables included physiological effects (blood pressure, heart rate, oral temperature, pupil diameter), subjective effects using visual analog scales (VAS), the short form of the Addiction Research Center Inventory (ARCI), the Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire (VESSPA-SSE), and the Sensitivity to Drug Reinforcement Questionnaire (SDRQ), and psychomotor performance (Maddox wing, psychomotor vigilance task). We observed that methylone could significantly increase blood pressure and heart rate and induce pleasurable effects, such as stimulation, euphoria, wellbeing, enhanced empathy, and altered perception. Methylone exhibited an effect profile similar to MDMA, with a faster overall onset and earlier disappearance of subjective effects. These results suggest that abuse potential of methylone is comparable to that of MDMA in humans. Clinical Trial Registration: ; Identifier: NCT05488171.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Usefulness of Oral Fluid for Measurement of Methylone and Its Metabolites, Correlation with Plasma Drug Concentrations and the Effect of Oral Fluid pH

  • Sprega, Giorgia
  • Di Giorgi, Alessandro|||0000-0003-2997-221X
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Tini, Anastasio
  • Pichini, Simona
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Lo Faro, Alfredo Fabrizio|||0000-0002-0240-5277
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
The aim of this study was to investigate methylone and its metabolites concentration in oral fluid following controlled increasing doses, focusing on the effect of oral fluid pH. Samples were obtained from a clinical trial where twelve healthy volunteers participated after ingestion of 50, 100, 150 and 200 mg of methylone. Concentration of methylone and its metabolites 4-hydroxy-3-methoxy-N-methylcathinone (HMMC) and 3,4-methylenedioxycathinone in oral fluid were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were estimated, and the oral fluid-to-plasma ratio (OF/P) at each time interval was calculated and correlated with the oral fluid pH using data from our previous study in plasma. Methylone was detected at all time intervals after each dose; MDC and HMMC were not detectable after the lowest dose. Oral fluid concentrations of methylone ranged between 88.3-503.8, 85.5-5002.3, 182.8-13,201.8 and 214.6-22,684.6 ng/mL following 50, 100, 150 and 200 mg doses, respectively, peaked between 1.5 and 2.0 h, and were followed by a progressive decrease. Oral fluid pH was demonstrated to be affected by methylone administration. Oral fluid is a valid alternative to plasma for methylone determination for clinical and toxicological studies, allowing for a simple, easy and non-invasive sample collection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sweat Testing for the Detection of Methylone after Controlled Administrations in Humans

  • Di Giorgi, Alessandro|||0000-0003-2997-221X
  • Sprega, Giorgia
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Di Trana, Annagiulia|||0000-0002-8456-0827
  • Varì, Maria Rosaria|||0000-0001-8641-0761
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Pichini, Simona
  • Zaami, Simona|||0000-0001-5741-7139
  • Lo Faro, Alfredo Fabrizio|||0000-0002-0240-5277
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
The aim of this study was to determine the excretion of methylone and its metabolites in sweat following the ingestion of increasing controlled doses of 50, 100, 150 and 200 mg of methylone to twelve healthy volunteers involved in a clinical trial. Methylone and its metabolites 4-hydroxy-3-methoxy-N-methylcathinone (HMMC) and 3,4-methylenedioxycathinone (MDC) were analyzed in sweat patches by liquid chromatography-tandem mass spectrometry. Methylone and MDC were detected in sweat at 2 h and reached their highest accumulation (C) at 24 h after the administration of 50, 100, 150 and 200 mg doses. In contrast, HMMC was not detectable at any time interval after each dose. Sweat proved to be a suitable matrix for methylone and its metabolites' determination in clinical and toxicological studies, providing a concentration that reveals recent drug consumption.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans

  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Lo Faro, Alfredo Fabrizio|||0000-0002-0240-5277
  • Berardinelli, Diletta
  • Sprega, Giorgia
  • Malaca, Sara
  • Pichini, Simona
  • Huestis, Marilyn A.|||0000-0003-2137-4645
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
The aim of this study is to define, for the first time, human methylone and HMMC plasma pharmacokinetics following controlled administration of 50-200 mg methylone to 12 male volunteers. A new LC-MS/MS method was validated to quantify methylone, MDMA, and their metabolites in plasma. The study was a randomized, cross-over, double-blinded and placebo-controlled study, with a total of 468 plasma samples collected. First, 10 µL of MDMA-d, MDA-d and methylone-d internal standards were added to 100 µL of plasma. Two mL of chloroform and ethyl acetate 9:1 (v / v) were then added, mixed well and centrifuged. The supernatant was fortified with 0.1 mL acidified methanol and evaporated under nitrogen. Samples were reconstituted with a mobile phase and injected into the LC-MS/MS instrument. The method was fully validated according to OSAC guidelines (USA). Methylone plasma concentrations increased in a dose-proportional manner, as demonstrated by the increasing maximum concentration (Cmax) and area under the curve of concentrations (AUC). Methylone Cmax values were reported as 153, 304, 355 and 604 ng/mL, AUC0-24 values were reported as 1042.8, 2441.2, 3524.4 and 5067.9 h·ng/mL and T values as 5.8, 6.4, 6.9 and 6.4 h following the 50, 100, 150 and 200 mg doses, respectively. Methylone exhibited rapid kinetics with a Tmax of 1.5 h for the 50 mg dose and 2 h approximately after all the other doses. HMMC exhibited faster kinetics compared to methylone, with a Cmax value that was 10-14-fold lower and an AUC0-24 value that was 21-29-fold lower. Methylone pharmacokinetics was linear across 50-200 mg oral doses in humans, unlike the previously described non-linear oral MDMA pharmacokinetics. An LC-MS/MS method for the quantification of methylone, MDMA and their metabolites in human plasma was achieved. Methylone exhibited linear pharmacokinetics in humans with oral doses of 50-200 mg.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

GC-MS/MS Determination of Synthetic Cathinones, 4-chloromethcathinone, N-ethyl Pentedrone, and N-ethyl Hexedrone in Oral Fluid and Sweat of Consumers under Controlled Administration: Pilot Study

  • Nuñez-Montero, Melani
  • Lombroni, Claudia
  • La Maida, Nunzia|||0000-0003-0127-4225
  • Rotolo, Maria Concetta
  • Pichini, Simona
  • Papaseit, Esther|||0000-0003-2620-4274
  • Hladun, Olga|||0000-0002-6230-5876
  • Ventura, Mireia|||0000-0003-1133-6872
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Marchei, Emilia|||0000-0002-7158-6032
This study presents a validated GC-MS/MS method for the detection and quantification of 4-chloromethcathinone or clephedrone (4-CMC), N-ethyl Pentedrone (NEP), and N-ethyl Hexedrone (NEH, also named HEXEN) in oral fluid and sweat and verifies its feasibility in determining human oral fluid concentrations and pharmacokinetics following the administration of 100 mg of 4-CMC orally and 30 mg of NEP and NEH intranasally. A total of 48 oral fluid and 12 sweat samples were collected from six consumers. After the addition of 5 μL of methylone-d and 200 μL of 0.5 M ammonium hydrogen carbonate, an L/L extraction was carried out using ethyl acetate. The samples, dried under a nitrogen flow, were then derivatized with pentafluoropropionic anhydride and dried again. One microliter of the sample reconstituted in 50 μL of ethyl acetate was injected into GC-MS/MS. The method was fully validated according to international guidelines. Our results showed how, in oral fluid, the two cathinones taken intranasally were absorbed very rapidly, within the first hour, when compared with the 4-CMC which reached its maximum concentration peak in the first three hours. We observed that these cathinones were excreted in sweat in an amount equivalent to approximately 0.3% of the administered dose for 4-CMC and NEP. The total NEH excreted in sweat 4 h after administration was approximately 0.2% of the administered dose. Our results provide, for the first time, preliminary information about the disposition of these synthetic cathinones in the consumers' oral fluid and sweat after controlled administration.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure

  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Papaseit, Esther|||0000-0003-2620-4274
  • Olesti, Eulàlia|||0000-0001-8677-9964
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Ventura, Mireia|||0000-0003-1133-6872
  • Grifell, Marc|||0000-0001-9815-5761
  • Fonseca, Francina|||0000-0002-0779-6545
  • Torrens, Marta
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Carbón, Xoán|||0000-0003-1652-5488
Methylone is a synthetic cathinone that is usually used as a substitute for conventional psychostimulants, such as MDMA. Chemically, methylone is considered the β-keto analogue of MDMA, with which it presumably shares similar pharmacological effects. To date, the available data about the human pharmacology of methylone in humans are very scarce and are mainly derived from user experiences, published in internet forums or intoxication reports. Thus, an observational-naturalistic study was conducted to evaluate the acute pharmacological effects and determine biomarkers of exposure in oral fluid of methylone after oral self-administration in comparison to MDMA. Methylone induced the prototypical psychostimulant and empathogenic effects commonly associated with MDMA, although they were of lower intensity. Oral fluid concentrations of methylone can be considered a suitable biomarker of acute exposure, and oral fluid has been proven to be a useful biological matrix of detection. Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.